AXL and non-small cell lung carcinoma: In a random subgroup of the 40 EGFR-mutant NSCLC tumors, including both FGFR1high and FGFR1low expressing tumors, we analyzed the co-occurrence of other reported EGFR-TKI resistance mechanisms such as T790M, MET amp, HER2 amp, and AXL expression (Supplementary Table 5).